ArticleMolecules (Basel, Switzerland)2020
Flavonoids as Novel Efflux Pump Inhibitors and Antimicrobials Against Both Environmental and Pathogenic Intracellular Mycobacterial Species.
Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 61 citations in OpenAlex.
- Flavonoids in treatment of tuberculosis: from molecular mechanisms to structure activity relationships.Molecular biology reports · 2026Review
- Bioactivity-Guided Isolation of Flavone Glycoside fromMolecules (Basel, Switzerland) · 2025Article
- Functional Approaches to Discover New Compounds via Enzymatic Modification: Predicted Data Mining Approach and Biotransformation-Guided Purification.Molecules (Basel, Switzerland) · 2025Review
- Chlorpromazine inhibits the plasmid-mediated oqxAB multidrug efflux pump in Escherichia coli isolates of Egyptian patients with utis.BMC microbiology · 2025Article
- Citrus flavonoids for overcoming breast cancer resistance to methotrexate: identification of potential targets of nobiletin and sinensetin.Discover oncology · 2025Article
- Flavonoids as Promising Natural Compounds for Combating Bacterial Infections.International journal of molecular sciences · 2025Review
- UHPLC-HRMS/MS Chemical Fingerprinting of the Bioactive Partition from CultivatedMolecules (Basel, Switzerland) · 2024Article
- Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.Current topics in medicinal chemistry · 2024Review
- Antimicrobial resistance expansion in pathogens: a review of current mitigation strategies and advances towards innovative therapy.JAC-antimicrobial resistance · 2023Review
- Phytochemicals as Invaluable Sources of Potent Antimicrobial Agents to Combat Antibiotic Resistance.Life (Basel, Switzerland) · 2023Review
- C-1 Substituted isoquinolines potentiate the antimycobacterial activity of rifampicin and ethambutol.Frontiers in antibiotics · 2023Article
- The culmination of multidrug-resistant efflux pumps vs. meager antibiotic arsenal era: Urgent need for an improved new generation of EPIs.Frontiers in microbiology · 2023Review
- Bacterial Multidrug Efflux Pumps at the Frontline of Antimicrobial Resistance: An Overview.Antibiotics (Basel, Switzerland) · 2022Review
- Luteolin increases susceptibility to macrolides by inhibiting MsrA efflux pump in Trueperella pyogenes.Veterinary research · 2022Article
- Antibacterial Modes of Herbal Flavonoids Combat Resistant Bacteria.Frontiers in pharmacology · 2022Review
- Flavonoids as Inhibitors of Bacterial Efflux Pumps.Molecules (Basel, Switzerland) · 2021Review
- Efflux Pump Inhibition and Resistance Modulation inAntibiotics (Basel, Switzerland) · 2021Article
- Antimicrobial Activity of Extracts from thePlants (Basel, Switzerland) · 2021Article
- Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment.Polymers · 2021Review
- Interactions with Microbial Proteins Driving the Antibacterial Activity of Flavonoids.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Therapeutic treatment options for opportunistic non-tuberculous mycobacterial (NTM) infection and/or serious mycobacterial infections such as tuberculosis (TB) and leprosy are limited due to the spread of antimicrobial resistance mechanism. Plant-derived natural compounds as prospective efflux pump inhibitors may present a promising adjunct to conventional chemotherapy by enhancing mycobacterial susceptibility to antibiotics. This study served to evaluate the antimicrobial and resistance-modifying profile of a range of plant-derived flavonoids against the mycobacterial model strains:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.